Artemis DNA, Inc. (“Artemis DNA” or the “company”), a leading global diagnostic laboratory company, announced today that they have made the difficult decision to close their Houston, Texas facility. “This was certainly
The $250 million contract gives Artemis DNA exclusivity to commercialize and distribute Trucheck Pragma and Cancertrack liquid biopsy tests in the USA and Vietnam. Artemis DNA, Inc. (“Artemis DNA” or the
Artemis DNA, Inc. (“Artemis DNA” or the “company”), the US-based leading genetics company, proudly announced today that they have been selected as the winner of the Association of Corporate Growth (ACG)
Artemis DNA will begin offering groundbreaking cutting-edge genetic testing and early cancer detection technology to the people of Vietnam. Artemis DNA, Inc. (“Artemis DNA” or the “company”), a full-service, accredited, high complexity
Artemis DNA’s two facilities, in Irvine, California and Houston, Texas, are now both CLIA and CAP accredited. Artemis DNA, Inc. (“Artemis DNA” or the “company”), a full-service, accredited, high complexity clinical
Furthering its strong commitment to ESG initiatives, clinical diagnostic laboratory company becomes first U.S. corporate customer for EV-maker VinFast with reservation for 100 vehicles. Irvine, Calif., January 8, 2022 — Artemis
Irvine, Calif., November 30, 2021 — Artemis DNA, Inc. (“Artemis DNA” or the “company”), a full-service, accredited, high complexity clinical diagnostic laboratory company providing proprietary Next Generation Sequencing (NGS) genetic and diagnostic
Irvine, Calif., November 30, 2021 — Artemis DNA, Inc. (“Artemis DNA” or the “company”), a full-service, accredited, high complexity clinical diagnostic laboratory company providing proprietary Next Generation Sequencing (NGS) genetic and diagnostic
Irvine, Calif., November 4, 2021 — Artemis DNA, Inc. (“Artemis DNA” or the “company”), a full-service, accredited, high complexity clinical diagnostic laboratory company providing proprietary Next Generation Sequencing (NGS) genetic and
Irvine, Calif., October 12, 2021 — Artemis DNA, Inc. (“Artemis DNA” or the “company”), a full-service, accredited, high complexity clinical diagnostic laboratory company providing proprietary Next Generation Sequencing (NGS) genetic and diagnostic
Irvine, Calif., August 9, 2021 — Artemis DNA, Inc. (“Artemis DNA” or the “company”), a full-service, accredited, high complexity clinical diagnostic laboratory company providing proprietary Next Generation Sequencing (NGS) genetic and
